Osteoporosis in gastric cancer patients is often overlooked or even neglected despite its high prevalence in these patients. Considering that old age, malnutrition, chronic disease, chemotherapy, decreased body mass index and gastrectomy are independent risk factors for osteoporosis, it is reasonable that the prevalence of osteoporosis in gastric cancer patients would be high. Many surviving patients suffer from back pain and pathological fractures, which are related to osteoporosis. Fractures have obvious associated morbidities, negative impact on quality of life, and impose both direct and indirect costs. In the era of a >55.6% 5-year survival rate of gastric cancer and increased longevity in gastric cancer patients, it is very important to eliminate common sequelae such as osteoporosis. Fortunately, the diagnosis of osteoporosis is well established and many therapeutic agents have been shown to be effective and safe not only in postmenopausal females but also in elderly males. Recently, effective treatments of gastric cancer patients with osteoporosis using bisphosphonates, which are commonly used in postmenopausal woman, were reported.
Introduction
Gastric cancer is one of the most common cancers in the world. Although relatively decreasing in prevalence, it is still the second most common cause of death from cancer in the world.
The incidence of gastric cancer is very high in East Asia, and it is a major burden in countries, such as Korea. (1) Although the overall prognosis of gastric cancer is poor in Western countries, the 5-year survival rate for those who received operative treatment in Korea is 55.6%. In cases of early gastric cancer, the survival rate is more than 90% in Korea due to early diagnosis and aggressive surgical intervention. (2) However, many surviving patients unfortunately suffer from sequelae caused by the surgical procedure. Weight loss, 
The Prevalence of Osteoporosis and Fractures in Gastric Cancer or Postgastrectomy Patients
The overall prevalence of osteoporosis in Korean gastric cancer patients older than 50 years of age was 39.6%. (5) 
Malabsorption and malnutrition
Removal of the gastric antrum with anastomosis to the duode- 
Hyperparathyroidism
Hyperparathyroidism is associated with osteoporosis. The para- Bone formation marker levels were generally lower for the patients who received chemotherapy than for the patients who did not. (11) In conclusion, systemic adjuvant chemotherapy in postgastrectomy cancer patients may account for the uncoupling of the markers of bone formation during the early postgastrectomy period, and it is probable that the chemotherapeutic agents contribute to the more severe bone loss noted for patients who received chemotherapy. Calcitonin has osteoclast-inhibiting effects. Decreased calcitonin may favor bone resorption. One study found that the serum calcitonin levels were significantly reduced in postgastrectomy patients.
Other
The destruction of gastric acid after gastrectomy also might result in osteoporosis. Epidemiologic studies suggest an association between the use of protein pump inhibitors, low bone density, and fractures. (31) The proposed mechanism of action is decreased gastric acidity causing a decrease in absorption of calcium although this theory has been questioned yet.
Screening and Diagnosis of Osteoporosis in Gastric Cancer
Gastric cancer patients over 50 years of age should be screened for the risk factors for fracture and bone mineral density by DXA. Table 2 . (32) DXA is the gold standard for the non-invasive diagnosis of os- 
Management of Osteoporosis in Gastric Cancer
The management algorithm for osteoporosis in gastric cancer patients is shown in Fig. 1 . All gastric cancer patients with T scores between -1.0 and -2. Table 4 . It is well known that postgastrectomy patients have higher risks of both hip and vertebral fractures. (13, 14) The first goal in managing osteoporosis in gastric cancer patients is to restore adequate nutrition and prevent hyperparathyroidism to prevent further bone loss. The final goal is to prevent fractures and maintain a healthy life to improve quality of life in gastric cancer patients.
Physical activity
Physical activity is necessary for bone formation and maintenance throughout life. Weight training has been shown to induce a small increase in BMD at some, but not all skeletal sites. Walking has not demonstrated to increase BMD or to reduce fracture risk, but improvements in mobility, muscle function, and balance may Table 5 .
Most gastric cancer patients experience a rapid weight loss during the immediate postoperative period. They also experience lack of appetite, dyspepsia, altered intestinal motility, and dysphagia, which are explanatory factors of the low food intake. 
Pharmacologic intervention
Bisphosphonates, selective estrogen receptor modulators 
Bisphosphonates
Bisphosphonates are stable analogues of pyrophosphate with a strong affinity for bone apatite; these agents inhibit bone resorption by reducing the recruitment and activity of osteoclasts and increasing apoptosis of osteoclasts. (37, 38) The bones formed while patients are receiving bisphosphonates treatment is histologically normal. Further research is needed to help define the magnitude of the excessive risk of fracture in patients with gastric cancer. Furthermore, the best treatment or prevention schedule for osteoporosis in gastric cancer patients has not been clearly defined because there is not sufficient evidence. Thus, prospective data are needed to determine which pharmacologic intervention is more effective and safe.
Alendronate
These efforts will lead to improving the quality of life of long term survival gastric cancer patients.
